Rafael Holdings is focused on developing novel cancer and immune therapies. The company owns the Barer Institute, and is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd. Through the Barer Institute, the company is developing a pipeline of compounds focused on the regulation of cancer and immune metabolism.

Rafael Holdings invests in novel cancer therapeutics that have the potential to improve and extend the lives of patients

Rafael Holdings invests in novel cancer therapeutics that have the potential to improve and extend the lives of patients.

News

Press Release
News Coverage